ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2020

Abstract Number: 1279

Clinical Characteristics and Impact of the COVID-19 Pandemic in Systemic Lupus Erythematosus Patients in a Spanish Tertiary Hospital

Andrea Briones-Figueroa1, María Jesús García-Villanueva2, África Andreu Suárez1, Marina Tortosa-Cabañas2, Ana Corral-Bote2, Sandra Garrote-Corral2, Javier Bachiller-Corral1 and Mónica Vázquez1, 1Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, 2Hospital Universitario Ramón y Cajal, Madrid, Spain

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2020

Keywords: COVID-19, Systemic lupus erythematosus (SLE)

Session Information

Date: Sunday, November 8, 2020

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Data about incidence, clinical characteristics and outcome of patients with Systemic Lupus Erythematosus (SLE) with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease is scarce. We aimed to describe the infection rate, clinical characteristics and course of COVID-19 in patients with SLE.

Methods: An observational and descriptive study was conducted, which included patients with SLE from our Rheumatology Department. Clinical data and diagnosis of suspected or confirmed COVID-19 infection were extracted from electronic health records. We registered information about the clinical course of COVID-19 and performed a survey about the impact of the pandemic on the behavior and treatment of our patients.

Results: We included 251 patients with SLE, meeting the SLICC or 2019 ACR/EULAR criteria. 93,2% were women, with a mean age of 48,59 ± 13,25 years. 33 patients (13,1%) were diagnosed with suspected or confirmed COVID-19. Eight patients were confirmed by positive RT-PCR assay in nasopharyngeal swabs or by positive serology tests, while 25 patients were considered suspected cases with compatible clinical findings according to the general practitioner but without microbiological confirmation. The most frequent COVID-19 symptoms were cough (78,8%), fever (51,5%) and diarrhea (36,4%). 3 patients had contact with other SARS-CoV-2 positive individuals. Six patients (18,2%) had high disease activity according to SLEDAI-2K prior to the pandemic. 18,2% had secondary antiphospholipid syndrome. Five subjects (15,2%) attended the emergency department and all of them required hospital admission. One patient was admitted to the intensive care unit.  Nine patients (39,4%) received specific treatment for COVID-19. The most frequent antiviral drugs were hydroxychloroquine (24,2%) and azithromycin (21,2%). Three individuals received corticosteroids (9,1%) and one received anti-IL6 (3%). Two patients (6,1%) died due to COVID-19, who were receiving rituximab and mycophenolate mofetil, respectively. We compared the characteristics of SLE patients with and without COVID-19 as shown in the table. The survey was responded by 27 patients. During the current COVID-19 pandemic, 63% lived with their families with a median of 3 people (IQR 2-4), while 18,5% lived alone. 74,1% did complete lockdown and 18,5% occasionally left home interacting with other people. 55,5% had telematic follow-up by our Rheumatology department. Regarding rheumatological therapy, 74,1% maintained their usual treatment, 7,4% discontinued biological therapy and 3,7% completely interrupted their current treatment. 63% defined their rheumatic disease as stable whereas 37% experienced more flares during the period under review.

Conclusion: Despite the limited number of patients in our series, there does not appear to be an increased frequency of SARS-CoV-2 in SLE patients. A higher proportion of patients with biological treatment and a history of asthma was found among those who presented suspicious symptoms of COVID-19. This pandemic has had a major impact on the behavior and treatment of our patients; therefore, we emphasize the importance of encouraging patients to maintain current treatment and reinforce preventive measures.

Baseline and clinical characteristics of SLE patients with and without COVID-19.


Disclosure: A. Briones-Figueroa, None; M. García-Villanueva, None; �. Andreu Suárez, None; M. Tortosa-Cabañas, None; A. Corral-Bote, None; S. Garrote-Corral, None; J. Bachiller-Corral, None; M. Vázquez, None.

To cite this abstract in AMA style:

Briones-Figueroa A, García-Villanueva M, Andreu Suárez �, Tortosa-Cabañas M, Corral-Bote A, Garrote-Corral S, Bachiller-Corral J, Vázquez M. Clinical Characteristics and Impact of the COVID-19 Pandemic in Systemic Lupus Erythematosus Patients in a Spanish Tertiary Hospital [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/clinical-characteristics-and-impact-of-the-covid-19-pandemic-in-systemic-lupus-erythematosus-patients-in-a-spanish-tertiary-hospital/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-characteristics-and-impact-of-the-covid-19-pandemic-in-systemic-lupus-erythematosus-patients-in-a-spanish-tertiary-hospital/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology